Abstract

Because of the critical needs to develop alternatives to methadone for the maintenance treatment of opioid dependence and to expand the availability and accessibility of services in a cost-effective manner, we are proposing a 24-week randomized trial that will assess the clinical efficacy of alternative buprenorphine maintenance dosing strategies (daily versus thrice-weekly). The study conducted in a traditional maintenance program, compares daily buprenorphine maintenance dosing (Group 1) and thrice-weekly maintenance dosing (Group 2). To assess whether opioid dependent patients without major psychopathology or dependence on alcohol, sedatives or cocaine can benefit from less frequent dosing, subjects (N=90) will be required to meet stringent eligibility and exclusion criteria and will be stratified by gender and employment status prior to random assignment to treatment. Counseling conditions will be manual-guided and carefully supervised to insure adherence to the study protocol and the integrity of the treatment approaches. Major outcomes include retention in the clinical trial, reductions in illicit opioid and other drug use, and reductions in HIV risk behavior.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA009803-03
Application #
2458441
Study Section
Special Emphasis Panel (SRCD (52))
Project Start
1995-08-01
Project End
1999-07-31
Budget Start
1997-08-01
Budget End
1999-07-31
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost

  Institution

Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520

  Publications

Edelman, E Jennifer; Dinh, An T; Moore, Brent A et al. (2012) Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians. J Addict Med 6:159-65
Schackman, Bruce R; Leff, Jared A; Polsky, Daniel et al. (2012) Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med 27:669-76
Sullivan, Lynn E; Botsko, Michael; Cunningham, Chinazo O et al. (2011) The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 56 Suppl 1:S54-61
Sullivan, Lynn E; Moore, Brent A; O'Connor, Patrick G et al. (2010) The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict 19:53-8
Barry, Declan T; Irwin, Kevin S; Jones, Emlyn S et al. (2010) Opioids, chronic pain, and addiction in primary care. J Pain 11:1442-50
Wang, Emily A; Moore, Brent A; Sullivan, Lynn E et al. (2010) Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. J Gen Intern Med 25:670-4
Jones, Emlyn S; Moore, Brent A; Sindelar, Jody L et al. (2009) Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 99:132-40
Barry, Declan T; Irwin, Kevin S; Jones, Emlyn S et al. (2009) Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med 24:218-25
Sullivan, Lynn E; Moore, Brent A; Chawarski, Marek C et al. (2008) Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 35:87-92
Fiellin, David A; Moore, Brent A; Sullivan, Lynn E et al. (2008) Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict 17:116-20

Showing the most recent 10 out of 19 publications